AU Patent

AU2020204786A1 — Induction of sustained local inflammation

Assigned to Ascendis Pharma Oncology Division AS · Expires 2021-06-10 · 5y expired

What this patent protects

The present invention relates to a water-insoluble controlled-release pattern recognition receptor agonist ("PRRA") or its pharmaceutically acceptable salt or a pharmaceutical composition comprising such water-insoluble controlled-release PRRA or its pharmaceutical accept…

USPTO Abstract

The present invention relates to a water-insoluble controlled-release pattern recognition receptor agonist ("PRRA") or its pharmaceutically acceptable salt or a pharmaceutical composition comprising such water-insoluble controlled-release PRRA or its pharmaceutical acceptable salt for use in the treatment of a cell-proliferation disorder, wherein the water-insoluble controlled-release PRRA, its pharmaceutically acceptable salt or the pharmaceutical composition is administered by intra-tissue administration, and wherein such intra-tissue administration results in local inflammation; and to related aspects.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020204786A1
Jurisdiction
AU
Classification
—
Expires
2021-06-10
Drug substance claim
No
Drug product claim
No
Assignee
Ascendis Pharma Oncology Division AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.